Trial · NCT01559363
Results by group289
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 289
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing | TEAEs | 24 | Participants | |
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | TEAEs | 8 | Participants | |
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | TEAEs | 5 | Participants | |
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing | SAE | 1 | Participants | |
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | SAE | 0 | Participants | |
| Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | SAE | 0 | Participants | |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: Pre-dose | 0 | Standard Deviation 0 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: Pre-dose | 0 | Standard Deviation 0 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: 1 hour post-dose | 4.39 | Standard Deviation 2.78 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: 1 hour post-dose | 8.41 | Standard Deviation 5.84 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: 2 hours post-dose | 10.1 | Standard Deviation 10.2 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: 2 hours post-dose | 18.6 | Standard Deviation 12.0 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: 4 hours post-dose | 21.1 | Standard Deviation 14.8 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: 4 hours post-dose | 33.1 | Standard Deviation 8.24 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: 8 hours post-dose | 25.4 | Standard Deviation 12.1 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: 8 hours post-dose | 44.3 | Standard Deviation 7.50 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 1: 24 hours post-dose | 21.9 | Standard Deviation 9.69 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 1: 24 hours post-dose | 35.5 | Standard Deviation 7.10 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | Day 14: Pre-dose | 90.3 | Standard Deviation 29.1 | nanograms per milliliter (ng/mL) |
| Phase 1b: Pharmacokinetics (PK): Plasma Concentrations of Tesevatinib 100 mg and 150 mg | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | Day 14: Pre-dose | 164 | Standard Deviation 45.4 | nanograms per milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01559363/results